3621 related articles for article (PubMed ID: 11735348)
1. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
2. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
Bertolini A; Ottani A; Sandrini M
Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?
Fiorucci S; Meli R; Bucci M; Cirino G
Biochem Pharmacol; 2001 Dec; 62(11):1433-8. PubMed ID: 11728379
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept.
Celotti F; Laufer S
Pharmacol Res; 2001 May; 43(5):429-36. PubMed ID: 11394934
[TBL] [Abstract][Full Text] [Related]
5. Dual acting anti-inflammatory drugs.
Leone S; Ottani A; Bertolini A
Curr Top Med Chem; 2007; 7(3):265-75. PubMed ID: 17305569
[TBL] [Abstract][Full Text] [Related]
6. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy.
Celotti F; Durand T
Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):147-62. PubMed ID: 14518558
[TBL] [Abstract][Full Text] [Related]
7. Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept.
Gaddi A; Cicero AF; Pedro EJ
Arch Gerontol Geriatr; 2004; 38(3):201-12. PubMed ID: 15066307
[TBL] [Abstract][Full Text] [Related]
8. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
Galli G; Panzetta G
G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs.
Charlier C; Michaux C
Eur J Med Chem; 2003; 38(7-8):645-59. PubMed ID: 12932896
[TBL] [Abstract][Full Text] [Related]
10. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors.
de Gaetano G; Donati MB; Cerletti C
Trends Pharmacol Sci; 2003 May; 24(5):245-52. PubMed ID: 12767724
[TBL] [Abstract][Full Text] [Related]
11. Non steroidal anti-inflammatory and anti-allergy agents.
Kontogiorgis CA; Hadjipavlou-Litina DJ
Curr Med Chem; 2002 Jan; 9(1):89-98. PubMed ID: 11860351
[TBL] [Abstract][Full Text] [Related]
12. [Coxibs: cyclooxygenase-2 inhibitors].
Turnheim K
Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
[TBL] [Abstract][Full Text] [Related]
13. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
Blain H; Jouzeau JY; Netter P; Jeandel C
Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
[TBL] [Abstract][Full Text] [Related]
14. COX-2 specific inhibitors offer improved advantages over traditional NSAIDs.
Urban MK
Orthopedics; 2000 Jul; 23(7 Suppl):S761-4. PubMed ID: 10914695
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2: a therapeutic target.
Turini ME; DuBois RN
Annu Rev Med; 2002; 53():35-57. PubMed ID: 11818462
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors.
van der Bijl P; van der Bijl P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
Meyer-Kirchrath J; Schrör K
Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
[TBL] [Abstract][Full Text] [Related]
19. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation.
Wallace JL; Chapman K; McKnight W
Br J Pharmacol; 1999 Mar; 126(5):1200-4. PubMed ID: 10205009
[TBL] [Abstract][Full Text] [Related]
20. Safety of anti-inflammatory treatment--new ways of thinking.
Brune K
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i16-20. PubMed ID: 14752171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
